SIRPalpha/SHPS1 (D6I3M) Rabbit mAb

SHP-substrate 1 (SHPS1, SIRPα) is a single-pass membrane protein and member of both the immunoglobulin superfamily and the signal regulatory protein (SIRP) family. Following growth hormone stimulation or integrin binding, SHPS1 is phosphorylated at several tyrosine residues within its cytoplasmic tail. These phosphorylation events promote association between SHPS1 and multiple signaling proteins, including SHP-1, SHP-2, Grb2 and Shc via their SH2 domains (1-4). Recruitment of SHP-1 and SHP-2 results in SHPS1 dephosphorylation and suppression of tyrosine kinase signaling (1-3,5). The tyrosine kinase JAK2 associates with SHPS1 via its carboxy terminus and phosphorylates SHPS1 in response to extracellular stimuli (5). Research studies show that Src associates with and may phosphorylate SHPS1 in response to insulin (4). In macrophages, SHPS1 can form a complex with the Src pathway adaptor protein SKAP2, Fyn-binding protein FYB, and the tyrosine kinase PYK2 (6). The SHPS1 extracellular domain contains at least three IgG-like domains that interact with CD47, a ubiquitously expressed, integrin-associated protein that acts as a repressive cue in both immune and neuronal cells (7,8). The interaction between CD47 and SHPS1 on opposing cells can inhibit cellular migration (9), promote "tethering" between macrophages and target cells during engulfment (10), facilitate self versus non-self recognition (11), and maintain immune homeostasis (12). SHPS1 plays a critical role in modulating the immune response and inflammation, and may play a role in neuronal development (13,14). The interaction between SHPS1 and CD47 may be an exploitable target in cancer therapy (15-17). 1.Kharitonenkov, A. et al. (1997) Nature 386, 181-6. 2.Ochi, F. et al. (1997) Biochem Biophys Res Commun 239, 483-7. 3.Takada, T. et al. (1998) J Biol Chem 273, 9234-42. 4.Shen, X. et al. (2009) Mol Cell Proteomics 8, 1539-51. 5.Stofega, M.R. et al. (2000) J Biol Chem 275, 28222-9. 6.Timms, J.F. et al. (1999) Curr Biol 9, 927-30. 7.Seiffert, M. et al. (1999) Blood 94, 3633-43. 8.Vernon-Wilson, E.F. et al. (2000) Eur J Immunol 30, 2130-7. 9.Motegi, S. et al. (2003) EMBO J 22, 2634-44. 10.Tada, K. et al. (2003) J Immunol 171, 5718-26. 11.van Beek, E.M. et al. (2005) J Immunol 175, 7781-7. 12.Legrand, N. et al. (2011) Proc Natl Acad Sci U S A 108, 13224-9. 13.Sarfati, M. et al. (2008) Curr Drug Targets 9, 842-50. 14.Matozaki, T. et al. (2009) Trends Cell Biol 19, 72-80. 15.Hara, K. et al. (2011) Cancer Res 71, 1229-34. 16.Willingham, S.B. et al. (2012) Proc Natl Acad Sci U S A 109, 6662-7. 17.Weiskopf, K. et al. (2013) Science 341, 88-91.